Amgen’s KRAS Mutation Study: A Potential Game-Changer in Colorectal Cancer Treatment

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. is conducting a Phase 3 clinical study titled A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation. The study aims to compare progression-free survival in patients with KRAS p.G12C mutated colorectal cancer, testing combinations of sotorasib and panitumumab against standard treatments.

The study tests two experimental treatments: Sotorasib, an oral drug, and Panitumumab, administered intravenously. These are compared against standard treatments like Trifluridine and Tipiracil or Regorafenib, which are also oral medications.

This interventional study is randomized with a parallel assignment model, focusing on treatment as its primary purpose. There is no masking involved, meaning all parties are aware of the treatment allocations.

The study began on April 19, 2022, with an active but not recruiting status. The last update was submitted on August 12, 2025, indicating ongoing progress and data collection.

For investors, this study could influence Amgen’s stock performance positively if results show significant benefits of the new treatment. The competitive landscape includes other companies developing KRAS-targeted therapies, which could impact market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.